Visioneering Technologies Inc (ASX:VTI) names Mark Rapoport as new CFO

Visioneering Technologies – 27/06/17

Visioneering Technologies Inc (ASX:VTI), has appointed Mr Mark Rapoport as the Company’s new CFO, overseeing its financial management. Mr Rapoport’s appointment comes at an exciting time in the Company’s growth, with Visioneering looking to continue significant national and global sales and manufacturing expansion.

READ MORE

Visioneering Technologies Inc (ASX:VTI) listing ceremony highlights.

Finance News Network – 04/04/17

Highlights from the Visioneering Technologies Inc (ASX:VTI) listing day ceremony, covering key speeches and the bell ringing ceremony.

WATCH HERE

ASX welcomes Visioneering Technologies Inc (ASX:VTI) to the exchange.

Finance News Network – 04/04/17

Australian Securities Exchange (ASX) Compliance Manager Adrian Smythe, welcomes Visioneering Technologies Inc (ASX:VTI) to the exchange.

WATCH HERE
Visioneering Technologies Inc (ASX:VTI): explanation of the price board before ringing the bell

Finance News Network – 04/04/17

Australian Securities Exchange (ASX) Compliance Advisor Chris Hobbs, explains the price board and its relevance to the listing day ceremony, prior to the ringing of the bell.

WATCH HERE

Visioneering Technologies Inc (ASX:VTI) – CEO welcome speech

Finance News Network – 04/04/17

Visioneering Technologies Inc (ASX:VTI) CEO, Dr Stephen Snowdy discusses the Company’s technology and strength as part of the listing day ceremony.

WATCH HERE

Visioneering Technologies Inc (ASX:VTI) lists on the ASX

Finance News Network – 04/04/17

Visioneering Technologies Inc (ASX:VTI) CEO, Dr Stephen Snowdy, discusses the Company’s technology, strengths and reason for listing on the Australian Securities Exchange (ASX) with Finance News Network interviewer Carolyn Hubert.

WATCH HERE
Visioneering debuts on ASX

**CNBC – 28/03/2017**

Visioneering Technologies’ CEO Stephen Snowdy discusses the company’s ASX debut on CNBC. He says the A$33.3 million raised through the IPO will be used to broaden the Company’s US distribution, and talks to the problems that its NaturalVue MF lenses look to solve.

[READ MORE](#)

---

Stephen Snowdy

**Switzer TV – 27/03/2017**

US-based medical device company Visioneering Technologies has just completed an IPO in Australia. CEO Stephen Snowdy joined Switzer TV to discuss why they raised the money in Australia, and more about the business.

[READ MORE](#)

---

Contacts lenses for 7-year-olds in the sights of Visioneering’s $33 ASX IPO

**Australian Financial Review – 27/03/2017**

A huge increase in the short-sightedness among children has bolstered the business case for Visioneering, a US maker of multifocal contact lenses that listed on the ASX on Tuesday, raising $33 million at an $88 million market capitalisation. The Georgia-based company had its NaturalVue multifocal contact lenses approved by the Food and Drug Administration in 2015 and made $US216,000 sales in calendar year 2016 to optometrists addressing two markets: over-40s sufferers of presbyopia, which is a loss of near vision; and under-18s with paediatric myopia or nerd-sightedness in children which is reaching plague proportions in much of the world.

[READ MORE](#)
New ASX entrant Visioneering Technologies, is expanding its focus and hopes to be selling its innovative contact lenses in Australia by the end of the year. US-based Visioneering Technologies (ASX:VTI) has already launched its NaturalVue branded lenses in the United States, which has a $US5 billion market for multi-focal lenses of the two types the company specialises in.

Visioneering Technologies $33 million, expands infrastructure

Visioneering Technologies, Inc., manufacturer of the NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, has raised A$33.3 million following the close of its fully underwritten Initial Public Offering (IPO).

The IPO will provide capital as the company expands and accelerates its US launch of the NaturalVue Multifocal daily disposable contact lenses for adults with presbyopia and children with myopia and launches additional contact lens products, according to a press release from the company.

Medical device company Visioneering Technologies successfully raises $33.3 million in fully underwritten Initial Public offering

Visioneering Technologies, Inc. (VTI), a US-based medical device company engaged in the design, manufacture, sale and distribution of its propriety NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, has successfully raised A$33.3 million following the close of its fully underwritten Initial Public Offering (IPO).
US medical device company Visioneering Technologies, Inc. to list on ASX – Initial Public Offer opens

Mass Device – 02/03/2017

Visioneering Technologies this week priced its A$33.3 million initial public offering on the Australian Securities Exchange. The US-based contact lens maker said it’s offering 79.4 million shares of its Class A common stock priced at ¢42 apiece.

READ MORE

US medical device company, Visioneering Technologies, Inc. to list on ASX – Initial Public Offer opens

Business Wire – 01/03/2017

Visioneering Technologies, Inc. (VTI), a US-based medical device company, is pleased to announce the opening of its fully underwritten Initial Public Offering (IPO) to raise A$33.3 million. The IPO will provide capital as VTI broadens its US launch of its NaturalVue™ Multifocal 1 Day (NaturalVue MF) daily disposable contact lenses for adults with presbyopia (age-related loss of near vision) and children with myopia (near-sightedness).

READ MORE

Down Under’s lure for US medical Device issuers

The Sydney Morning Herald – 20/02/2017

Australia is consolidating its position as a market of choice for smaller US medical companies to go public, with another company, Visioneering Technologies, finalising an initial public offer.

Visioneering makes disposable contact lenses and is targeting markets worth at least $US3.4 billion among adults and $US2 billion-a-year among children.

READ MORE
Contact lens maker Visioneering Technologies Inc eyes ASX boards

Australian Financial Review—10/02/2017

Stockbroker Canaccord Genuity has started marketing one of the year’s first initial public offering candidates.

It is understood United States-based medical device company Visioneering Technologies Inc has been in front of local fund managers this week, as it goes about trying to raise $33.3 million fresh equity for a deal valuing the company at $88.2 million.

READ MORE